TP-317 is a first-in-class small molecule oral therapy in development for ulcerative colitis and Crohn’s Disease
RIDGEFIELD, CT – (July 23, 2020) – Thetis Pharmaceuticals LLC, a privately-held biopharmaceutical company focused on developing Resolvin-based therapies for inflammatory diseases, announced today that the European Patent Office has granted patent EP 3157936 providing composition of matter protection for TP-317 (Resolvins E1 magnesium lysinate) and use claims in a broad range of gastrointestinal (GI) diseases including ulcerative colitis and Crohn’s disease. National filings outside of the United States are underway.
Gary Mathias., co-founder and CEO of Thetis said, “This patent provides Thetis with long-term patent coverage of TP-317 in the U.S. and Europe, which combined account for more than 80% of the market opportunity for therapies to treat inflammatory bowel disease. Furthermore, our patent estate effectively blocks the patentability of other novel Resolvins salts that enhance stability, thus providing the equivalent of field of use for endogenous E-series and D-series Resolvins.”
The active agent in TP-317 is Resolvin E1 (RvE1), an endogenous immunoresolvent discovered by biomedical researchers at Harvard Medical School. When administered therapeutically in preclinical models of IBD, RvE1 activates multiple pathways to resolve inflammation and promote tissue repair without compromising the host’s ability to fight infection. Based on its unique, non-immunosuppressive mechanism of action, TP-317 is differentiated from approved and investigational IBD drugs currently in development. Phase 1 studies indicate that RvE1 is safe and well tolerated in healthy volunteers. Clinical studies in IBD patients are planned for 2022.
About Inflammatory Bowel Disease
IBD is a chronic autoimmune disease characterized by inflammation and ulceration of the intestines that includes ulcerative colitis and Crohn’s Disease. Symptoms typically include diarrhea mixed with blood, abdominal pain, increased bowel movements and in severe cases, weight loss and fatigue. Currently available medications alleviate inflammation and reduce symptoms, but do not provide a cure or prevent long-term complications, and some have serious adverse effects, including increased risk of severe infection and malignancy. As a result, there continues to be a high unmet medical need for additional oral agents that are safe and effective for the induction and maintenance of remission of ulcerative colitis and Crohn’s disease.
About Thetis Pharmaceuticals
Thetis is a biopharmaceutical company dedicated to improving the lives of patients suffering from inflammatory diseases. Thetis’ proprietary HEALER™ technology platform enables the pharmaceutical development of Resolvins, a class of endogenous lipid mediators that promote inflammation resolution and tissue repair. Thetis’ HEALER™ technology overcomes the stability, manufacturing, and formulation hurdles that have limited the development of Resolvins as pharmaceutical agents, unlocking their robust pharmacology to be developed as first-in-class drugs with composition of matter patent protection.
For more information, please visit Thetis Pharmaceuticals’ website (http://thetispharma.com) and follow Thetis on Twitter (@thetispharma).
Senior Director of Business Development